Carsgen Therapeutics Holdings Ltd. · HKEX:2171
Carsgen Therapeutics — Investor Day (November 2025)
79 slides from Carsgen Therapeutics's investor day presentation, Nov 19, 2025
Slide 1: Key Technological R&D to Overcome Challenges in CAR-T Therapy Development
Key Technological R&D to Overcome Challenges in CAR-T Therapy Development Zonghai LI November 19, 2025 CARsgen Therapeutics (Stock Code: 2171.HK) Making Cancer Curable
Slide 2: Disclaimer
Disclaimer THIS DOCUMENT IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT INTENDED TO BE, AND SHALL NOT BE CONSTRUED AS, AN OFFER, INDUCEMENT, INVITATION, SOLICITATION, COMMITMENT OR ADVERTISEMENT WITH RESPECT TO THE PURCHASE, SUBSCRIPTION OR SALE OF ANY SECURITY AND NO PART OF IT SHALL FORM THE BASIS
Slide 3: Content
Content • Underlying Rationale and Establishment of the THANK-u Plus Technology Platform • Next-Generation Technology Platform for Solid Tumors • Application Potential of LADAR® Technology • New Allogeneic Pipeline and Its Preclinical Studies Confidential Copyrights reserved by CARsgen 3
Slide 4: Allogeneic CAR-T Platforms
Allogeneic CAR-T Platforms Com CARsgen Allogen Poseid Caribou Bioheng SANA BRL Crispr pany Therapeu e a Biosciences Therapeu Biotechn Medicine Therapeuti tics Therape Therap tics ology cs utics eutics Techn TCR+HLA- TCR+CD5 TCR Approach 1: TCR+HLA- TCR+HLA- TCR+HLA TCR+B2M+ ology I+/-2 +/- 2 KO, +B2
Slide 5: Insights from CT0590 Clinical Data
Insights from CT0590 Clinical Data • NKG2A CAR-T cells showed robust expansion in two patients, but failed to expand in two others—one of the patient achieved expansion only after a dose escalation. This suggests that a CAR targeting only NKG2A may be insufficient to induce robust expansion in all p
Slide 6: CARsgen's Novel Strategy for Allogeneic CAR-T
CARsgen's Novel Strategy for Allogeneic CAR-T Anti-CD19/CD20 scFv Anti-BCMA/NKG2A scFv Anti-NKG2A scFv NKi binder A NKi binder A HLA-I KO HLA-I KO TCR deletion TCR deletion CT1190B CT0596 TRAC NKG2 TRAC NKG2 A A B2M B2M Confidential Copyrights reserved by CARsgen 6
Slide 7: CARsgen's Novel Strategy for Allogeneic CAR-T
CARsgen's Novel Strategy for Allogeneic CAR-T Anti-CD19/CD20 scFv Anti-CD19/CD20 scFv Anti-C scFv NKi binder B NKi binder A HLA-I KO HLA-I KO TCR deletion TCR deletion CT1195E CT1192 HLA-II KO HLA-II KO TRAC CIITA TRAC CIITA B2M B2M Confidential Copyrights reserved by CARsgen 7
Slide 8: Goal 1: To Identify a Potent Blocker for Activated NK Cells
Goal 1: To Identify a Potent Blocker for Activated NK Cells aNK #1 (T:NK=1:2) aNK #2 (T:NK=1:2) 200000 UCAR-T 150000 UCAR-T Number of UCAR-T UCAR-T-HLA-E UCAR-T-HLA-E UCAR-T counts 150000 100000 100000 50000 50000 0 0 h h h h 24 48 24 48 rNK #1 (T:NK=1:2) rNK #2 (T:NK=1:2) 200000 UCAR-T 200000 UCAR-
Slide 9: T Cells Overexpressing CD47 are Ineffective in Resisting NK Cell Rejection
T Cells Overexpressing CD47 are Ineffective in Resisting NK Cell Rejection NK #1 (T:NK=1:2) NK #2 (T:NK=1:2) 40000 8000 UTD UTD Cell number(1*10^4) Number of UCAR-T CD47 CD47 30000 6000 20000 4000 10000 2000 0 0 24h 72h 24h 72h In co-culture assays with NK cells at 24 and 72 hours, CD47-overexpressi
Slide 10: NKi Binder A Confers Strong Protection to Allogeneic CAR-T Cells
NKi Binder A Confers Strong Protection to Allogeneic CAR-T Cells Against NK Cell-Mediated Rejection Cell Stem Cell . 2023;30(11):1538-1548.e4 120 NK #1 (T:NK=1:2) NK #2 (T:NK=1:2) 100 15000 UTD 10000 UTD Percentage(%) TIM3 TIM3 80 Number of UCAR-T Number of UCAR-T NKi binder A 8000 NKi binder A 1000
Slide 11: Robust and Sustained Expansion of U-CART Across Varying NKG2A Expression Levels
Robust and Sustained Expansion of U-CART Across Varying NKG2A Expression Levels Achieved by a Combination of NKi Binder A and an NKG2A CAR High NKG2A Moderate NKG2A Low NKG2A expression expression expression Confidential Copyrights reserved by CARsgen 11
Slide 12: Both CT1192 and CT1195E Demonstrate Robust NK Cell Resistance and Anti-Tumor Efficacy
Both CT1192 and CT1195E Demonstrate Robust NK Cell Resistance and Anti-Tumor Efficacy Confidential Copyrights reserved by CARsgen 12
Slide 13: Novel Technologies and Strategies for Solid Tumors
Novel Technologies and Strategies for Solid Tumors Zhao Y, et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotech, 2024 TGFβ TGFβ Receptor DNRII DNRII/IL- 10R TGFβ TGFβ IL10R IL10R RI RII 1 2 P P Smad2/3 P Smad2/3 STAT3 CAR T
Slide 14: In Vivo Efficacy of Different-Generation CLDN18.2-Targeting CAR-T Cells in Tumor-Bearing Mice
In Vivo Efficacy of Different-Generation CLDN18.2-Targeting CAR- T Cells in Tumor-Bearing Mice HGC27-A2 1# 2# 3000 (1) UTD 3000 3000 Tumor volume(mm3) Tumor volume(mm3) (2) CT041 Tumor Volume(mm3) 2000 2000 (3) CT041-DNRII 2000 (4) CT041-DNRII/IL10R 1000 1000 0 0 13 17 20 24 27 31 34 38 47 13 17 20
Slide 15: Targeting Cancer-Associated Fibroblasts to Potentiate CAR-T Cell Efficacy in Solid Tumors
Targeting Cancer-Associated Fibroblasts to Potentiate CAR-T Cell Efficacy in Solid Tumors Addressing fibroblasts in the tumor microenvironment represents a promising strategy to unlock the therapeutic potential of CAR-T cells and other agents. FAP (Fibroblast activating protein alpha) Liu Y, et al.
Slide 16: LADAR®: Technology Platform for Precise Targeting
LADAR®: Technology Platform for Precise Targeting LADAR® Technology Local Action Driven by Artificial Receptor LADAR®, like SynNotch , induces the expression of a therapeutic protein in the presence of its specific triggering antigen. This leads to localized activity of the therapeutic protein, ther
Slide 17: LADAR® for Localized CAR and Therapeutic Protein Expression
LADAR® for Localized CAR and Therapeutic Protein Expression Applications of the LADAR system in CAR-T therapies Dual receptor AND-gate LADAR-CAR-T cells with precise tumor killing (in vivo effects) Normal Tumor tissue U251-EGFRvIII+ 3000 UTD Tumor Volume(mm3) B7H3-CAR-T Distraction 2000 EGFRvIII-LAD
Slide 18: LADAR® Enables Precise, Localized Expression of Cytokines and Other Therapeutic Proteins
LADAR® Enables Precise, Localized Expression of Cytokines and Other Therapeutic Proteins IL-12 800 CAR-T IL12-LADAR-CAR-T Tumor 600 (pg/ml) Reshaping 400 inflamed tumor CAR LADAR microenvironment 200 TF 0 Tumor cytolysis TF 5 3 1 7 Cytokine secretion PC F/ ep uh R -h H -G /P SK p1 C PL e -h SK LADAR
Slide 19: Allogeneic CAR-T Candidates for Multiple Targets
Allogeneic CAR-T Candidates for Multiple Targets CAR-T for solid tumors：CLDN18.2, GPC3, DLL3, B7H3, FAP, NKG2DL… CAR-T for hematologic malignancies：NKG2DL，CLL1, CD19/BCMA,BCMA/GPRC5D, CD19/CD20… CAR-T for autoimmune diseases：CD19/CD20, CD19/BCMA, BCMA Confidential Copyrights reserved by CARsgen 19
Slide 20: CLL1-Targeted Allogeneic CAR-T CT1390B Effectively Eliminates Acute Myeloid Leukemia Cells
CLL1-Targeted Allogeneic CAR-T CT1390B Effectively Eliminates Acute Myeloid Leukemia Cells CT1390B demonstrates significant anti-tumor efficacy, regardless of the presence or absence of NK cells. UTD+NK CLL-1 CLL-1+NK CT1390B CT1390B+NK D6 In the presence of NK cells, CT1390B exhibits superior survi
Slide 21: NKG2D UCAR-T Effectively Eliminates Acute Myeloid Leukemia Cells
NKG2D UCAR-T Effectively Eliminates Acute Myeloid Leukemia Cells Benchmark, Benchmark THANK-u THANK-u UTD Conv +NK Plus Plus +NK D9 Day 21 60 CAR T cell counts/ul PB D15 40 20 0 1 2 3 4 5 D24 1. UTD 2. Benchmark (Conv.) 3. Benchmark +NK 4. THANK-u Plus 5. THANK-u Plus +NK D30 Confidential Copyrights
Slide 22: NKG2DL is Universally Expressed Across AML Cell Lines
NKG2DL is Universally Expressed Across AML Cell Lines MICA/B ULBP-3 ULBP-4/RAET1E ULBP-1 ULBP-2/5/6 THP-1 MV-4-11 KG-1 Molm13 Confidential Copyrights reserved by CARsgen 22
Slide 23: NKG2DL Expression is Detected in All Tumor Cell Lines Tested
NKG2DL Expression is Detected in All Tumor Cell Lines Tested AsPC-1 BxPC3 MIA-PaCa2 PANC-1 AGS HGC-27 HuH-7 PLC/PRF/5 Ctrl MICA/B Antibody ULBP-1 ULBP-2/5/6 ULBP-3 ULBP-4 Confidential Copyrights reserved by CARsgen 23
Slide 24: A Potential Best-in-Class BCMA/CD19 CAR-T
A Potential Best-in-Class BCMA/CD19 CAR-T Feng J, et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial, Nat Med, 2025. 12 out of 15 (80%) patients achieved a DORIS response within 3 months. CD19/BCMA CD19/BCMA (Ben
Slide 25: Preclinical Efficacy Evaluation of Allogeneic CLDN18.2 CAR-T
Preclinical Efficacy Evaluation of Allogeneic CLDN18.2 CAR-T CLDN18.2-UCAR T (Conv.) CLDN18.2-UCAR T (Conv.) + NK HGC27-A2 UTD 4000 4000 4000 3000 Tumor volume(mm3) Tumor volume(mm3) Tumor volume(mm3) 3000 3000 Tumor Volume(mm3) 3000 2000 2000 2000 2000 p<0.0001 1000 1000 1000 1000 2e6 NK 0 0 0 (i.v
Slide 26: Summary and Outlook
Summary and Outlook • Our proprietary allogeneic CAR-T strategy holds promise for better addressing the challenges in the widespread application of CAR-T therapy. • Next-generation strategies for solid tumors, such as Armored CAR-T, FAP targeting, and combination/sequential therapy with other agents
Slide 27: Comprehensive CMC Enablement for CAR-T: From Development to Industry
Comprehensive CMC Enablement for CAR-T: From Development to Industry November 19, 2025 Making Cancer Curable
Slide 28: An Integrated CAR-T CMC Platform: Process Development and Analytical Testing
An Integrated CAR-T CMC Platform: Process Development and Analytical Testing
Slide 29: Full-Platform Process Development
Full-Platform Process Development From Raw Materials to Final Product Autologous CAR-T UCAR-T CT053/CT041/CT071… CT0596/CT1190B/CT1192/CT0890... Plasmid Lentiviral sgRNA Cas9 Cryopreserv Vector ation Media Confidential Copyrights reserved by CARsgen 29
Slide 30: Full-Platform Process Development: Plasmid, Viral Vector, sgRNA & Cas9 Process Platforms
Full-Platform Process Development: Plasmid, Viral Vector, sgRNA & Cas9 Process Platforms Plasmid Platform Lentiviral Vector Platform ◼ Utilizes an Animal-Origin Free (AOF) single- ◼ Batch production capacity reaches use fermentation process. up to 1012 TU. ◼ Capable of supplying material for hundred
Slide 31: Full-Platform Process Development: Autologous CAR-T Process Platform
Full-Platform Process Development: Autologous CAR-T Process Platform Simultaneous Activation & Transduction 30-Hour Production Purificati on, Fill, Leukap Separ Cryopres Release heresis ation ervation Testing Relea Rapid se & Process Infusi CT071 on Purificati on, Fill, Leukap Separ Cryopres Release
Slide 32: Full-Platform Process Development: UCAR-T Process Platform
Full-Platform Process Development: UCAR-T Process Platform Cell Selection Cell Activation Viral Gene Expansion Formulation, Transduction Knockout and Transportation Cryopreser vation Shipping & ※ Fully Closed Distribution Processing System Leukapheresis (from Healthy ※ Automated Key Unit Donors) Pat
Slide 33: Full-Platform Process Development: Proprietary Cell Cryopreservation Medium
Full-Platform Process Development: Proprietary Cell Cryopreservation Medium The in-house developed cryopreservation medium ensures long-term stability and quality of CAR-T cell products. 100 CARsgen 1.5 Com-1 相对细胞扩增倍数 80 Fold Viability % Com-2 Cell细胞活率(%) 1.0 Relative Cell 60 Expansion 40 0.5 20 0 0
Slide 34: Full-Platform Analytics and Quality Control: An Integrated Analytical Testing Platform
Full-Platform Analytics and Quality Control: An Integrated Analytical Testing Platform Our platform provides comprehensive, precise, and efficient analytical methods and testing data, ensuring robust support throughout the entire lifecycle of our cell therapy products, from R&D and clinical developm
Slide 35: Claudin18.2 Detection Kit Development: Addressing the Unmet Need for a Companion Diagnostic
Claudin18.2 Detection Kit Development: Addressing the Unmet Need for a Companion Diagnostic (Class III Medical Device) Early Product Nov 2022: Type Testing Jun 2024: ISO 13485 Certification Development; for Registration Obtained; Establishment of Completed Aug 2024: Kit Clinical Trial Completed CARs
Slide 36: RCL (Replication Competent Lentivirus) Testing (Indicator Cell Culture Assay)
RCL (Replication Competent Lentivirus) Testing (Indicator Cell Culture Assay) • Compliant with FDA regulatory requirements • Extended 28-day culture period • High detection sensitivity Enabled by our integrated testing platform: • In-house developed test kits • Internally established and validated m
Slide 37: Analytical Development, AD
Analytical Development, AD Integrated Multi- Comprehensive Multi- Full Lifecycle Central Technology National Regulatory 高学历团队构成 Dimensional Testing Support Integration Hub Compliance System Encompassing dozens of Covering method Connecting method Meets the multi-faceted GxP test items including deve
Slide 38: Bio-sample Analysis, BA
Bio-sample Analysis, BA Compliance Technical Capabilities Scale • GLP/GCP as the foundational framework • Comprehensive sample processing expertise for • Successfully processed single • Adherence to FDA 21 CFR Part 58+. diverse matrices: whole blood, serum, plasma, batches exceeding 1,800 samples •
Slide 39: Quality Control, QC
Quality Control, QC Culture Media & Reference Standards & Reagent Management In-house Control Materials Management QC Laboratory Instrument & Management OOS/OOT/AD Management Equipment Management System Testing & Monitoring Method Qualification and Validation • Products: CAR-T, Lentiviral Vectors, P
Slide 40: Full-Spectrum Compliance and Quality System
Full-Spectrum Compliance and Quality System
Slide 41: Full-Spectrum Compliance and Quality System
Full-Spectrum Compliance and Quality System Pharmaceutical Quality Management System Technology Transfer Management System Regulatory Submission and Inspection Management System Information System Management System EHS Management System (Environment, Health, and Safety) Confidential Copyrights reser
Slide 42: Full-Spectrum Compliance and Quality System: Pharmaceutical Quality Management System
Full-Spectrum Compliance and Quality System: Pharmaceutical Quality Management System Pharmaceutical Quality Management System Organization & Personnel: Facilities & Equipment: Environmental Control: Materials Management: Personnel Training, Plant & Facilities, Lifecycle Cleanliness Classification,
Slide 43: Full-Spectrum Compliance and Quality System: Pharmaceutical Quality Management System
Full-Spectrum Compliance and Quality System: Pharmaceutical Quality Management System Control Strategy for Cell Therapy Products Knowledge GMP Core Elements Quality Risk Management Management Contamination Manufacturing Quality Control Control Strategy Control Strategy Strategy Zero Tolerance for Pr
Slide 44: Full-Spectrum Compliance and Quality System: Technology Transfer Management System
Full-Spectrum Compliance and Quality System: Technology Transfer Management System CGMP facility Technology Transfer Experience & Achievements CGMP facility CMC R&D center (Xuhui) Executed 2 domestic site transfers (from Xuhui to Jinshan) Completed technology transfer to 2 US-based CDMOs Shanghai Pe
Slide 45: Full-Spectrum Compliance and Quality System: Global Regulatory Submission System
Full-Spectrum Compliance and Quality System: Global Regulatory Submission System Supported by multiple Coverage of Chinese and international registration applications prestigious designations, accelerating the R&D process China Progress • China: 2 Breakthrough Therapy designations, 2 Priority ▪ INDs
Slide 46: Full-Spectrum Compliance and Quality System: Information System Management System
Full-Spectrum Compliance and Quality System: Information System Management System From Digitalization to Intelligentization: Building an Efficient, Reliable, and Continuously Evolving Modern Manufacturing Operation System. WMS (Warehouse MES (Manufacturing DMS & TMS (Document End-to-End Traceability
Slide 47: Full-Spectrum Compliance and Quality System: EHS Management System
Full-Spectrum Compliance and Quality System: EHS Management System to Ensure Comprehensive Protection Emergency Response Safety in Production Establish a robust safety emergency Implement comprehensive safety management system with simulation measures across all operations, protecting drills. both t
Slide 48: Industrial Evolution and Scaling
Industrial Evolution and Scaling
Slide 49: Commercial Production: Comprehensive and Integrated Manufacturing Capabilities
Commercial Production: Comprehensive and Integrated Manufacturing Capabilities Shanghai Integrated Smart Cell Jinshan Facility Manufacturing Center In 2019, this site was granted China's The future facility will be an Integrated first Drug Manufacturing License for a Smart Cell Manufacturing Center
Slide 50: Industrialization Breakthrough: The CMC Smart Manufacturing Platform
Industrialization Breakthrough: The CMC Smart Manufacturing Platform Our digital platform enables seamless, end-to-end management and data visualization from "Raw Material" to "Patient," driving an efficient and reliable productivity engine. 1. Prescription Management Hospital / Medical CARsgen Cell
Slide 51: Industrialization Breakthrough: Closed, Automated, Integrated Process Development Platform
Industrialization Breakthrough: Closed, Automated, Integrated Process Development Platform Production area cleanliness grade B to C Closed Reduced production space required Automation Increased production success rate Integrated Reduced number of personnel per batch Optimal selection Supply chain ma
Slide 52: CAR-T Industrialization Evolution and Future Prospects
CAR-T Industrialization Evolution and Future Prospects Looking ahead, we will focus on process automation, Empowering CAR-T CMC development through digitalized management, and industry chain multi-dimensional capabilities including full-platform collaboration to further reduce production costs, tech
Slide 53: Data-Driven, Evidence-Based: A Practical Review of Allogeneic CAR-T Clinical Data Across Multiple Cancers
Data-Driven, Evidence-Based: A Practical Review of Allogeneic CAR-T Clinical Data Across Multiple Cancers November 19, 2025 Making Cancer Curable
Slide 54: Content
• Significant Features of CAR-T Cells as Living Drugs • Core Advantages of Allogeneic CAR-T and Key Clinical Application Considerations CONTENT • CARsgen's Pioneering Solutions • Early Efficacy of CARsgen's Technology Platform Across Various Indications • Scalability of CARsgen's Technology Platform
Slide 55: Significant Features of CAR-T Cells as Living Drugs
Significant Features of CAR-T Cells as Living Drugs
Slide 56: CAR-T Cells Are "Living" Drugs, Fundamentally Distinct from Other Therapeutic Modalities
CAR-T Cells Are "Living" Drugs, Fundamentally Distinct from Other Therapeutic Modalities • The greatest appeal of CAR-T as a living drug lies in its capacity for expansion. Unlike traditional medications that require repeated administration to maintain therapeutic concentrations, CAR-T cells possess
Slide 57: Core Advantages of Allogeneic CAR-T and Key Clinical Application Considerations
Core Advantages of Allogeneic CAR-T and Key Clinical Application Considerations
Slide 58: Allogeneic CAR-T: Overcoming Industry Bottlenecks with Rapid Production, Lower Costs, and Off-the-Shelf Availability
Allogeneic CAR-T: Overcoming Industry Bottlenecks with Rapid Production, Lower Costs, and Off-the-Shelf Availability to Significantly Improve Patient Access Single-Batch • Compromised T-cell fitness in Production frail patients Multi-Patient Allogeneic CAR-T • Prolonged wait times carrying Applicabi
Slide 59: Existing Efficacy Gap between Allogeneic CAR-T and Autologous CAR-T
Existing Efficacy Gap between Allogeneic CAR-T and Autologous CAR-T Allogeneic BCMA CAR-T Autologous BCMA CAR-T Treatment and outcomes ALLO-715 P-BCMA-ALLO12 cilta-cel 3.2 x108 cells, N=241 All Arm**: 0.25-6 x106 cells/kg, Arm C**:2 x106 cells/kg 0.5-1 x106 cells/kg, N=973 N=72 N=23 23 (including 2
Slide 60: Relatively Limited Expansion of Allogeneic CAR-T in Patients
Relatively Limited Expansion of Allogeneic CAR-T in Patients • In allogeneic CAR-T, donor T cells will be recognized and rapidly eliminated by the host immune system (HvGR), which impacts CAR-T cell survival and results in limited expansion. • Compared to autologous CAR-T, in vivo persistence of all
Slide 61: Allogeneic CAR-T Faces HVGR Challenges in Clinical Applications
Allogeneic CAR-T Faces HVGR Challenges in Clinical Applications Expansion Challenge • The primary bottleneck in the clinical application of allogeneic CAR-T is 安全性挑 Host immune cells recognize 扩增挑战 Host-versus-Graft Response (HVGR). 战 allogeneic antigens GVH 异体CAR-T识别受者 HVGR;受者免疫系统通过HLA分子识 • HVGR im
Slide 62: CARsgen's Pioneering Solutions
CARsgen's Pioneering Solutions
Slide 63: THANK-uCAR® or THANK-u Plus: Innovative Allogeneic CAR-T Platform Aimed to Address HvGR
THANK-uCAR® or THANK-u Plus : Innovative Allogeneic CAR- T Platform Aimed to Address HvGR Target and Hinder the Attack of NK cells on Universal CAR-T cells (THANK-uCAR®) HvGR is the major challenge faced by Allogeneic CAR-T • B2M knockout to overcome HvGR from host T cells, but NK cells attack uCAR-
Slide 64: Early Efficacy of CARsgen's Technology Platform Across Various Indications
Early Efficacy of CARsgen's Technology Platform Across Various Indications
Slide 65: CT0590 (BCMA): First-Generation Product Built on the THANK-uCAR® Platform
CT0590 (BCMA): First-Generation Product Built on the THANK- uCAR® Platform High risk % Baseline Peak CAR # of % Bone marrow Patient cytogenetics NKG2A Best overall DOR copy number Dose (cells) prior smear plasma (Diagnosis) Y/N expression NK response (mo) (copies/µg lines cell at baseline cells gDNA
Slide 66: CT0596 (BCMA): Second-Generation Product Built on the THANK-u Plus Platform
CT0596 (BCMA): Second-Generation Product Built on the THANK-u Plus Platform • CT0596 demonstrated favorable tolerability: Safety ✓ NO ≥Grade 3 CRS ✓ NO ICANS or GvHD ✓ NO DLTs, no patients discontinuing treatment due to AE • As of June 24, 2025, 8 R/R MM patients who had received at least 3 prior li
Slide 67: CT0596 Treatment in Two Patients with R/R pPCL Resulting in sCR
CT0596 Treatment in Two Patients with R/R pPCL Resulting in sCR As of the data cutoff date (Oct 17, 2025), two patients with relapsed/refractory pPCL had been enrolled. pPCL-01 pPCL-02 Patient 62-year-old male, IgG-λ type 70-year-old male, κ light chain type ASCT + triple classes of drugs (PI, IMiD,
Slide 68: CT1190B: An Allogeneic CD19/CD20-Targeting CAR-T Cell Therapy (THANK-u Plus)
CT1190B: An Allogeneic CD19/CD20-Targeting CAR-T Cell Therapy (THANK-u Plus ) THANK-u Plus Platform Clinical Development Progress and Plans • THANK-u Plus demonstrates significantly enhanced expansion compared to THANK-uCAR® • An Investigator-Initiated Trial (IIT) of CT1190B • THANK-u Plus sustains
Slide 69: CT1190B Demonstrated Efficacy and Safety
CT1190B Demonstrated Efficacy and Safety Data cut-off: October 17, 2025. The primary safety signals were CRS, cytopenias, and infections. No DLTs were observed, and no other adverse reactions such as ICANS or GvHD were reported. ➢ Lymphodepletion Regimen: Fludarabine 30 mg/m² × 3 days + Cyclophospha
Slide 70: Pharmacokinetics at the Recommended Dose
Pharmacokinetics at the Recommended Dose Mean or Median Cmax Product Indication （copies/ug） CT1190B NHL 114564.5 (RD) (allogeneic) ALL-501 LBCL 1688 (allogeneic) relma-cel LBCL 25214.5~29693.5 (autologous) Kymriah LBCL 5210.33~6450 (autologous) At the recommended dose (full-intensity lymphodepletion
Slide 71: Registration and Development Plan for CT0596 and CT1190B
Registration and Development Plan for CT0596 and CT1190B • CT0596 Based on the strong clinical data from CT0596 Potential Indications: R/R PCL, R/R MM and CT1190B—particularly their robust Planned initiation of Phase IB registration study in 2026 expansion and favorable benefit-risk profiles Planned
Slide 72: Scalability of CARsgen's Technology Platform
Scalability of CARsgen's Technology Platform
Slide 73: CARsgen's Allogeneic CAR-T Platform Demonstrates High Scalability
CARsgen's Allogeneic CAR-T Platform Demonstrates High Scalability Screening and identifying regulatory pathways of NK cell surface molecules; optimizing platforms to resist NK cell activity through combinations of inhibitory and killing signals; refining platform applications across indications base
Slide 74: Deepening Our Presence in Hematologic Malignancies: Advancing into Acute Myeloid Leukemia
Deepening Our Presence in Hematologic Malignancies: Advancing into Acute Myeloid Leukemia Reduced normal ✓ Acute Myeloid Leukemia Disease Characteristics: Rapid Leukemic cells immune cells progression; patients in advanced stages exhibit an immunosuppressed state due to bone marrow occupation by leu
Slide 75: Expanding into Autoimmune Diseases: Leveraging Platform Advantages to Build Differentiation
Expanding into Autoimmune Diseases: Leveraging Platform Advantages to Build Differentiation NMOSD MG Multiple sclerosis Rheumatology & Neurology Immunology • Varying contributions of B cells and plasma • CT1190B: Currently in progress • CT059X, a dual-target BCMA cells across disease types • Additio
Slide 76: Expanding into Solid Tumors: Improving Accessibility and Efficacy for Late-Line Patients
Expanding into Solid Tumors: Improving Accessibility and Efficacy for Late-Line Patients CAR-T manufacturing • Late-line solid tumor patients often present with poor baseline conditions and rapid disease progression. A subset of patients experience disease progression during cell manufacturing, losi
Slide 77: Expanding into Solid Tumors: Broader Early-Line Applications
Expanding into Solid Tumors: Broader Early-Line Applications CARsgen’s Claudin18.2 IHC test kit with high sensitivity Gastric Cancer Pancreatic Cancer Bile Duct Cancer Moderate / high positivity (≥2+, ≥40%) Moderate / high positivity (≥2+, ≥40%) Moderate / high positivity (≥2+, ≥40%) 68% 55% 25% • C
Slide 78: Summary
Summary • As a living drug, CAR-T plays a critical role in the deep clearance of tumors through its expansion and the formation of an optimal effector-to-target ratio. • The greatest challenge faced by allogeneic CAR-T in clinical application is HVGR. Existing technologies require effective integrat
Slide 79: Making Cancer Curable
Making Cancer Curable oS cARSGEN